Log in to save to my catalogue

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell...

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a3d6902fdf494d03bb252c7609dbec45

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

About this item

Full title

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2023-03, Vol.14 (1), p.1359-12, Article 1359

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Bromodomain and extraterminal proteins (BET) play key roles in regulation of gene expression, and may play a role in cancer-cell proliferation, survival, and oncogenic progression. CC-90010-ST-001 (NCT03220347) is an open-label phase I study of trotabresib, an oral BET inhibitor, in heavily pretreated patients with advanced solid tumors and relapse...

Alternative Titles

Full title

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_a3d6902fdf494d03bb252c7609dbec45

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a3d6902fdf494d03bb252c7609dbec45

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-023-36976-1

How to access this item